GT Biopharma Inc. (GTBP)
NASDAQ: GTBPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GTBP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $6.33M
- EPS (TTM)
- -$128.61
- Dividend yield
- None
- 52-week range
- 2.87 – 23.60
- Day range
- 2.87 – 3.20
- Volume / Avg
- 39.69K / 78.16K
- Beta
- —
- Shares outstanding
- 2.14M
52-week range
GTBP stock today
Shares of GT Biopharma (GTBP) finished lower on Nov 20 at $2.96, a drop of 6.92% or $0.22 per share, versus the S&P 500's 3.70% decline. Shares are 87.5% below their 52-week high of $23.60 and 3.2% above the 52-week low of $2.87, near the bottom of the past year's range. GTBP is up 277.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 303.3%.
GT Biopharma has posted a net loss over the last twelve months (EPS of -$128.61), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About GT Biopharma
Company profileGT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Michael Martin Breen L.L.B.
- Headquarters
- San Francisco, CA
- Employees
- 1
- Website
- gtbiopharma.com
Financial highlights
Full financialsGT Biopharma reported a net loss of $28.4 million, compared with a loss of $13.2 million a year earlier. Diluted earnings per share came in at -$6.68.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-28.35M | $-13.16M | $-7.60M | $-20.88M | $-58.01M |
| EPS (diluted) | $-6.68 | $-6.94 | $-5.64 | $-19.66 | $-2.06 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$75.00+2433.78%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-1.98 vs —
GTBP news
All GTBP newsGT Biopharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KYNBKyntra Bio Inc. | 1.56 | -13.33% | $6.32M | vs GTBP |
| FBLGFibroBiologics Inc. | 0.705 | -15.06% | $6.34M | vs GTBP |
| ACXPAcurx Pharmaceuticals Inc. | 1.04 | +0.97% | $6.30M | vs GTBP |
| ADXNAddex Therapeutics Ltd ADR | 3.47 | +2.06% | $6.08M | vs GTBP |
| ENVBEnveric Biosciences Inc. | 1.35 | -4.26% | $6.04M | vs GTBP |
| BFRGBullfrog AI Holdings Inc. | 0.3556 | -8.84% | $6.65M | vs GTBP |
| XCURExicure Inc. | 0.9001 | -12.82% | $5.89M | vs GTBP |
| MTVAMetaVia Inc. | 1.01 | -7.34% | $6.81M | vs GTBP |
Indexes, lists and sector
GT Biopharma stock FAQ
What is GT Biopharma's stock price today?
GTBP last traded at $2.96 as of Nov 20, 4:00 PM EST, down 6.92% on the day. Prices are delayed at least 15 minutes.
Does GT Biopharma pay a dividend?
No. GT Biopharma does not currently pay a regular cash dividend.
Who is GT Biopharma's CEO?
Mr. Michael Martin Breen L.L.B. is the chief executive officer of GT Biopharma Inc., which has about 1 employees.
Has GTBP ever split its stock?
Yes. The most recent GTBP stock split was a 1-for-25 split on Sep 8, 2026, one of 3 splits on record.
What is the GTBP 52-week high?
The 52-week high for GTBP is $23.60 and the 52-week low is $2.87. The stock is currently 87.5% below its high.